Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 - Episode 9

New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

March 19, 2025

Shubham Pant, MD, Haley Ellis, MD , Amit Mahipal, MD, Darshil Shah, MD, MPH

Panelists discuss how the HERIZON-BTC-302 study demonstrated zanidatamab's efficacy in HER2-positive biliary tract cancer (BTC) with key end points presented at ASCO GI, while sharing insights on optimal dosing strategies and early real-world experience with this newly approved agent in the second-line setting.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Guiding Patients Through Advanced BTC Prognosis and Expectations

EP. 2: The Importance of Early Biomarker Testing in Managing Advanced BTC

EP. 3: Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

EP. 4: Expert Insights: Challenges With ctDNA Testing in BTC

EP. 5: Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

EP. 6: Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

EP. 7: Understanding HER2 Testing in BTC: Detection and Clinical Approaches

EP. 8: Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

Now Viewing

EP. 9: New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

EP. 10: Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

EP. 11: Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

EP. 12: Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

EP. 13: Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

Video content above is prompted by the following:

Zanidatamab was recently approved. What were some key end points from the HERIZON-BTC-302 study at ASCO GI and what are your impressions?
What is your dosing strategy with zanidatamab? Dr Ellis, can you share some highlights from a poster looking at optimizing zanidatamab’s dosing?
For those with experience using zanidatamab in the 2L, what has your experience been? What outcomes have you seen in patients so far?